Journal articles on the topic 'Zyflamend'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 31 journal articles for your research on the topic 'Zyflamend.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Puckett, Dexter, Mohammed Alquraishi, Samah Chahed, Dina Alani, Victoria Frankel, Brynn Voy, Dallas Donohoe, Jay Whelan, and Ahmed Bettaieb. "Zyflamend, a Unique Herbal Blend, Inhibits Adipogenesis Through the Coordinated Regulation of PKA and JNK." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 454. http://dx.doi.org/10.1093/cdn/nzaa045_087.
Full textBilen, Mehmet Asim, Sue-Hwa Lin, Dean G. Tang, Kinjal Parikh, Mong-Hong Lee, Sai-Ching J. Yeung, and Shi-Ming Tu. "Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series." Case Reports in Oncological Medicine 2015 (2015): 1–5. http://dx.doi.org/10.1155/2015/471861.
Full textEkmekcioglu, Suhendan, Chandrani Chattopadhyay*, Ugur Akar*, Abdul Gabisi, Robert A. Newman, and Elizabeth A. Grimm. "Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells." Nutrition and Cancer 63, no. 6 (August 2011): 940–49. http://dx.doi.org/10.1080/01635581.2011.586488.
Full textTague, Eric D., Allen K. Bourdon, Amber MacDonald, Maggie S. Lookadoo, Edward D. Kim, Wesley M. White, Paul D. Terry, Shawn R. Campagna, Brynn H. Voy, and Jay Whelan. "Metabolomics Approach in the Study of the Well-Defined Polyherbal Preparation Zyflamend." Journal of Medicinal Food 21, no. 3 (March 2018): 306–16. http://dx.doi.org/10.1089/jmf.2017.0062.
Full textHume, Anne L. "Zyflamend for prevention of prostate cancer: Studies show benefits, but larger trials needed." Pharmacy Today 20, no. 7 (July 2014): 30. http://dx.doi.org/10.1016/s1042-0991(15)30779-9.
Full textPuckett, Dexter L., Mohammed Alquraishi, Samah L. Chahed, Dallas R. Donohoe, Jay Whelan, and AHMED BAETTAIEB. "Zyflamend Induces Apoptosis in Pancreatic Cancer cells via Modulation of the JNK Pathway." FASEB Journal 34, S1 (April 2020): 1. http://dx.doi.org/10.1096/fasebj.2020.34.s1.09714.
Full textZhao, Yi, Dallas Donohoe, E.-Chu Huang, and Jay Whelan. "Zyflamend, a polyherbal mixture, inhibits lipogenesis and mTORC1 signalling via activation of AMPK." Journal of Functional Foods 18 (October 2015): 147–58. http://dx.doi.org/10.1016/j.jff.2015.06.051.
Full textKatz, A. E., P. M. Pierorazio, P. Masson, E. T. Goluboff, B. A. Stone, J. M. McKiernan, M. C. Benson, and C. A. Olsson. "Results of a phase I trial administering Zyflamend to subjects with high-grade prostatic intraepithelial neoplasia." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 14575. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14575.
Full textHuang, E.-Chu, Guoxun Chen, Seung Joon Baek, Michael F. McEntee, J. Jason Collier, Steven Minkin, John Biggerstaff, and Jay Whelan. "Zyflamend Reduces the Expression of Androgen Receptor in a Model of Castrate-Resistant Prostate Cancer." Nutrition and Cancer 63, no. 8 (November 2011): 1287–96. http://dx.doi.org/10.1080/01635581.2011.606956.
Full textHuang, E. Chu, Michael F. McEntee, and Jay Whelan. "Zyflamend, a Combination of Herbal Extracts, Attenuates Tumor Growth in Murine Xenograft Models of Prostate Cancer." Nutrition and Cancer 64, no. 5 (July 2012): 749–60. http://dx.doi.org/10.1080/01635581.2012.689413.
Full textBuckley, Michael R., Paul D. Terry, Stacy S. Kirkpatrick, Joshua D. Arnold, Michael M. McNally, Oscar H. Grandas, Michael B. Freeman, Mitchell H. Goldman, Jay Whelan, and Deidra JH Mountain. "Dietary supplementation with Zyflamend poly-herbal extracts and fish oil inhibits intimal hyperplasia development following vascular intervention." Nutrition Research 68 (August 2019): 34–44. http://dx.doi.org/10.1016/j.nutres.2019.06.001.
Full textMohebati, Arash, Joseph B. Guttenplan, Amit Kochhar, Zhong-Lin Zhao, Wieslawa Kosinska, Kotha Subbaramaiah, and Andrew J. Dannenberg. "Carnosol, a Constituent of Zyflamend, Inhibits Aryl Hydrocarbon Receptor–Mediated Activation of CYP1A1 and CYP1B1 Transcription and Mutagenesis." Cancer Prevention Research 5, no. 4 (February 28, 2012): 593–602. http://dx.doi.org/10.1158/1940-6207.capr-12-0002.
Full textYang, Peiying, Carrie Cartwright, Diana Chan, Mary Vijjeswarapu, Jibin Ding, and Robert A. Newman. "Zyflamend®-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation." Cancer Biology & Therapy 6, no. 2 (February 2007): 228–36. http://dx.doi.org/10.4161/cbt.6.2.3624.
Full textRafailov, Samuil, Sam Cammack, Brian A. Stone, and Aaron E. Katz. "The Role of Zyflamend, an Herbal Anti-inflammatory, as a Potential Chemopreventive Agent Against Prostate Cancer: A Case Report." Integrative Cancer Therapies 6, no. 1 (March 2007): 74–76. http://dx.doi.org/10.1177/1534735406298843.
Full textPuckett, Dexter, Mohammed Alquraishi, Dina S. Alani, Samah Chahed, Victoria D. Frankel, Dallas Donohoe, Brynn Voy, Jay Whelan, and Ahmed Bettaieb. "Zyflamend, a unique herbal blend, induces cell death and inhibits adipogenesis through the coordinated regulation of PKA and JNK." Adipocyte 9, no. 1 (January 1, 2020): 454–71. http://dx.doi.org/10.1080/21623945.2020.1803642.
Full textKunnumakkara, Ajaikumar B., Bokyung Sung, Jayaraj Ravindran, Parmeswaran Diagaradjane, Amit Deorukhkar, Sanjit Dey, Cemile Koca, et al. "Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets." International Journal of Cancer 131, no. 3 (November 9, 2011): E292—E303. http://dx.doi.org/10.1002/ijc.26442.
Full textYan, Jun, Bingxian Xie, Jillian L. Capodice, and Aaron E. Katz. "Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth." Prostate 72, no. 3 (June 8, 2011): 244–52. http://dx.doi.org/10.1002/pros.21426.
Full textBools, Lindsay, Ryan Buckely, Deidra J. Mountain, Stacy Kirkpatrick, Jay Whelan, Paul Terry, Michael B. Freeman, and Oscar Grandas. "PC218. A Polyherbal Dietary Supplement, Zyflamend, Inhibits Matrix Metalloproteinase Expression and Attenuates Intimal Hyperplasia in a Rodent Model of Vascular Disease." Journal of Vascular Surgery 61, no. 6 (June 2015): 175S. http://dx.doi.org/10.1016/j.jvs.2015.04.332.
Full textXue, Yanshi, Lin Yang, Junzun Li, Yilin Yan, Qinghui Jiang, Lan Shen, Shuai Yang, et al. "Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway." OncoTargets and Therapy Volume 11 (July 2018): 4413–29. http://dx.doi.org/10.2147/ott.s162255.
Full textBemis, Debra L., Jillian L. Capodice, Aristotelis G. Anastasiadis, Aaron E. Katz, and Ralph Buttyan. "Zyflamend®, a Unique Herbal Preparation With Nonselective OX Inhibitory Activity, Induces Apoptosis of Prostate Cancer Cells That Lack COX-2 Expression." Nutrition and Cancer 52, no. 2 (July 2005): 202–12. http://dx.doi.org/10.1207/s15327914nc5202_10.
Full textYang, Peiying, Zheng Sun, Diana Chan, Carrie A. Cartwright, Mary Vijjeswarapu, Jibin Ding, Xiaoxin Chen, and Robert A. Newman. "Zyflamend® reduces LTB 4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[α]anthracene (DMBA)-induced hamster cheek pouch model." Carcinogenesis 29, no. 11 (August 6, 2008): 2182–89. http://dx.doi.org/10.1093/carcin/bgn181.
Full textSandur, Santosh K., Kwang Seok Ahn, Haruyo Ichikawa, Gautam Sethi, Shishir Shishodia, Robert A. Newman, and Bharat B. Aggarwal. "Zyflamend, a Polyherbal Preparation, Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis Through Down-Regulation of NF-κ B Activation and NF-κ B–Regulated Gene Products." Nutrition and Cancer 57, no. 1 (May 4, 2007): 78–87. http://dx.doi.org/10.1080/01635580701268295.
Full textKim, Ji Hye, Byoungduck Park, Subash C. Gupta, Ramaswamy Kannappan, Bokyung Sung, and Bharat B. Aggarwal. "Zyflamend Sensitizes Tumor Cells to TRAIL-Induced Apoptosis Through Up-Regulation of Death Receptors and Down-Regulation of Survival Proteins: Role of ROS-Dependent CCAAT/Enhancer-Binding Protein-Homologous Protein Pathway." Antioxidants & Redox Signaling 16, no. 5 (March 2012): 413–27. http://dx.doi.org/10.1089/ars.2011.3982.
Full textAlquraishi, Mohammed, Dallas Donohoe, Brynn H. Voy, Jay Whelan, and Ahmed Bettaieb. "Decreased adiposity and enhanced glucose tolerance in Zyflamend treated mice." FASEB Journal 33, S1 (April 2019). http://dx.doi.org/10.1096/fasebj.2019.33.1_supplement.754.5.
Full textPuckett, Dexter L., Mohammed Alquraishi, Dina Alani, Samah Chahed, Dallas Donohoe, Brynn Voy, Jay Whelan, and Ahmed Bettaieb. "Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway." Cell Communication and Signaling 18, no. 1 (August 14, 2020). http://dx.doi.org/10.1186/s12964-020-00609-7.
Full textBettaieb, Ahmed Bettaieb, Dexter Puckett, Samah Chahed, and Jay Whelan. "Zyflamend Induces Apoptosis in Pancreatic Cancer Cells via Modulation of the JNK Pathway." FASEB Journal 33, S1 (April 2019). http://dx.doi.org/10.1096/fasebj.2019.33.1_supplement.lb282.
Full textBettaieb, Ahmed, Katelin Hubbard, Dexter Puckett, Presley Dowker, Dina Alani, Samah Chahed, Mohammed Alquraishi, and Jay Whelan. "Zyflamend Supplementation Alleviates High‐Fat Diet‐Induced Obesity and Impairment of Skeletal Muscle Insulin Sensitivity." FASEB Journal 35, S1 (May 2021). http://dx.doi.org/10.1096/fasebj.2021.35.s1.03978.
Full textPuckett, Dexter, Dina Alani, Samah Chahed, Victoria Frankel, Jay Whelan, and Ahmed Bettaieb. "Zyflamend Induces Apoptosis in Pancreatic Cancer cells via modulation of Endoplasmic Reticulum stress and Autophagy." FASEB Journal 32, S1 (April 2018). http://dx.doi.org/10.1096/fasebj.2018.32.1_supplement.664.1.
Full textHuang, E‐Chu, Michael F. McEntee, Seung J. Baek, and Jay Whelan. "Synergistic effect of Zyflamend® and hormone ablation therapy on prostate cancer regression: adjuvant therapy for standard care." FASEB Journal 23, S1 (April 2009). http://dx.doi.org/10.1096/fasebj.23.1_supplement.902.14.
Full textHuang, E‐Chu, Michael F. McEntee, and Jay Whelan. "Zyflamend®, a multi‐herb extract with anticancer properties, promotes cell cycle arrest in advanced human prostate cancer cells." FASEB Journal 22, S1 (March 2008). http://dx.doi.org/10.1096/fasebj.22.1_supplement.700.12.
Full textHuang, E.-Chu, Yi Zhao, Guoxun Chen, Seung Joon Baek, Michael F. McEntee, Steven Minkin, John P. Biggerstaff, and Jay Whelan. "Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells." BMC Complementary and Alternative Medicine 14, no. 1 (February 21, 2014). http://dx.doi.org/10.1186/1472-6882-14-68.
Full text